109
drug1 may increase the photosensitizing activities of drug2.	1
drug1 may increase the anticholinergic activities of drug2.	2
The bioavailability of drug2 can be decreased when combined with drug1.	3
The metabolism of drug2 can be increased when combined with drug1.	4
drug1 may decrease the vasoconstricting activities of drug2.	5
drug1 may increase the anticoagulant activities of drug2.	6
drug2 may increase the ototoxic activities of drug1.	7
The risk or severity of adverse effects can be increased when drug1 is combined with drug2.	8
drug2 may increase the hypoglycemic activities of drug1.	9
drug1 may increase the antihypertensive activities of drug2.	10
The serum concentration of the active metabolites of drug2 can be reduced when drug2 is used in combination with drug1 resulting in a loss in efficacy.	11
drug2 may decrease the anticoagulant activities of drug1.	12
The therapeutic efficacy of drug2 can be decreased when used in combination with drug1.	13
drug1 may decrease the bronchodilatory activities of drug2.	14
drug1 may increase the cardiotoxic activities of drug2.	15
drug2 may increase the central nervous system depressant (CNS depressant) activities of drug1.	16
drug1 may decrease the neuromuscular blocking activities of drug2.	17
drug1 can cause an increase in the absorption of drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects.	18
drug2 may increase the vasoconstricting activities of drug1.	19
drug2 may increase the QTc-prolonging activities of drug1.	20
drug2 may increase the neuromuscular blocking activities of drug1.	21
drug2 may increase the adverse neuromuscular activities of drug1.	22
drug2 may increase the stimulatory activities of drug1.	23
drug2 may increase the hypocalcemic activities of drug1.	24
drug1 may increase the atrioventricular blocking (AV block) activities of drug2.	25
drug1 may decrease the antiplatelet activities of drug2.	26
drug1 may increase the neuroexcitatory activities of drug2.	27
drug2 may increase the dermatologic adverse activities of drug1.	28
drug1 may decrease the diuretic activities of drug2.	29
drug1 may increase the orthostatic hypotensive activities of drug2.	30
The risk or severity of adverse effects can be increased when drug2 is combined with drug1.	31
drug1 may increase the sedative activities of drug2.	32
drug1 may increase the QTc-prolonging activities of drug2.	33
drug1 may increase the immunosuppressive activities of drug2.	34
drug1 may increase the neurotoxic activities of drug2.	35
The risk or severity of adverse effects can be increased when drug2 is combined with drug1.	36
drug2 may decrease the antihypertensive activities of drug1.	37
drug2 may increase the vasodilatory activities of drug1.	38
drug1 may increase the constipating activities of drug2.	39
drug2 may increase the respiratory depressant activities of drug1.	40
drug1 may increase the serotonergic activities of drug2.	41
drug1 may increase the hyperkalemic activities of drug2.	42
The serum concentration of drug2 can be increased when it is combined with drug1.	42
The protein binding of drug1 can be decreased when combined with drug2.	43
drug1 may increase the central neurotoxic activities of drug2.	44
drug2 may decrease effectiveness of drug1 as a diagnostic agent.	45
The risk or severity of adverse effects can be increased when drug1 is combined with drug2.	46
The metabolism of drug1 can be decreased when combined with drug2.	47
drug2 may increase the myopathic rhabdomyolysis activities of drug1.	48
The risk or severity of adverse effects can be increased when drug1 is combined with drug2.	49
drug2 may increase the fluid retaining activities of drug1.	50
drug2 may increase the hypercalcemic activities of drug1.	51
drug2 may decrease the analgesic activities of drug1.	52
drug2 may increase the antiplatelet activities of drug1.	53
drug1 may increase the bradycardic activities of drug2.	54
drug2 may increase the hyponatremic activities of drug1.	55
drug2 may increase the nephrotoxic activities of drug1.	57
drug2 may decrease the cardiotoxic activities of drug1.	58
drug1 bromide may increase the ulcerogenic activities of drug2.	59
drug1 may increase the hypotensive activities of drug2.	60
drug2 may decrease the stimulatory activities of drug1.	61
drug2 may decrease the vasodilatory activities of drug1.	62
drug2 may increase the myelosuppressive activities of drug1.	63
drug2 may increase the serotonergic activities of drug1.	64
drug2 may increase the excretion rate of drug1 which could result in a lower serum level and potentially a reduction in efficacy.	65
The risk or severity of adverse effects can be increased when drug1 is combined with drug2.	66
drug2 can cause a decrease in the absorption of drug1 resulting in a reduced serum concentration and potentially a decrease in efficacy.	67
drug2 may increase the hyperkalemic activities of drug1.	68
drug2 may increase the analgesic activities of drug1.	69
The therapeutic efficacy of drug2 can be decreased when used in combination with drug1.	70
drug2 may increase the hypertensive activities of drug1.	71
drug2 may decrease the excretion rate of drug1 which could result in a higher serum level.	72
The serum concentration of drug1 can be increased when it is combined with drug2.	73
drug1 may increase the fluid retaining activities of drug2.	74
The metabolism of drug2 can be increased when combined with drug1.	75
The serum concentration of drug2 can be decreased when it is combined with drug1.	75
drug1 hydrobromide may decrease the sedative activities of drug2.	76
The serum concentration of the active metabolites of drug2 can be increased when drug2 is used in combination with drug1.	77
drug2 may increase the hyperglycemic activities of drug1.	78
drug2 may increase the serotonergic activities of drug1.	79
drug2 may increase the hepatotoxic activities of drug1.	80
drug2 may increase the thrombogenic activities of drug1.	81
drug2 may increase the arrhythmogenic activities of drug1.	82
drug1 may increase the hypokalemic activities of drug2.	83
drug1 may increase the vasopressor activities of drug2.	84
drug1 may increase the tachycardic activities of drug2.	85
The risk of a hypersensitivity reaction to drug1 is increased when it is combined with drug2.	86
GiG 87
CrC 88
DdG 89
Dps 90
DlA 91
CtD 92
CbG 93
CuG 94
DrD 95
DaG 96
CpD 97
AdG 98
AuG 99
GcG 100
GpMF 101
PCiC 102
GpCC 103
Gr>G 104
CdG 105
DuG 106
GpPW 107
CcSE 108
AeG 109
